Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

K Bowrin, JB Briere, P Levy, A Millier, J Tardu… - Journal of Market …, 2020 - mdpi.com
Background: Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF)
imposes a substantial economic burden on the UK healthcare system. Objectives: An …
被引用次数：8 相关文章

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

K Bowrin, JB Briere, P Lévy, A Millier, J Tardu, M Toumi - 2020 - econpapers.repec.org
Background: Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF)
imposes a substantial economic burden on the UK healthcare system. Objectives: An …

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

K Bowrin, JB Briere, P Lévy, A Millier, J Tardu… - Journal of Market …, 2020 - hal.science
Background: Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF)
imposes a substantial economic burden on the UK healthcare system. Objectives: An …

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

K Bowrin, JB Briere, P Lévy, A Millier, J Tardu, M Toumi - 2020 - ideas.repec.org
Background: Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF)
imposes a substantial economic burden on the UK healthcare system. Objectives: An …

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

K Bowrin, JB Briere, P Levy, A Millier… - Journal of market …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF)
imposes a substantial economic burden on the UK healthcare system. Objectives An …
[PDF] academia.edu

[PDF][PDF] Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

K Bowrin, JB Briere, P Levy, A Millier, J Tardu, M Toumi - Policy, 2020 - academia.edu
Background: Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF)
imposes a substantial economic burden on the UK healthcare system. Objectives: An …

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

K Bowrin, JB Briere, P Levy, A Millier… - Journal of Market …, 2020 - Taylor & Francis
Background Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF)
imposes a substantial economic burden on the UK healthcare system. Objectives An …

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK.

K Bowrin, JB Briere, P Levy, A Millier… - Journal of Market …, 2020 - europepmc.org
Background Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF)
imposes a substantial economic burden on the UK healthcare system. Objectives An …
[HTML] nih.gov

[HTML][HTML] Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

K Bowrin, JB Briere, P Levy, A Millier… - Journal of Market …, 2020 - ncbi.nlm.nih.gov
Background Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF)
imposes a substantial economic burden on the UK healthcare system. Objectives An …
[PDF] hal.science

[PDF][PDF] Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

K Bowrin, JB Briere, P Levy, A Millier, J Tardu, M Toumi - Policy, 2020 - hal.science
Background: Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF)
imposes a substantial economic burden on the UK healthcare system. Objectives: An …